Stock Track | Keymed Biosciences Soars 5.17% Following Strong 2024 Annual Results and Pipeline Progress

Stock Track

Mar 27, 2025

Shares of Keymed Biosciences (HKEX: 02162) are soaring 5.17% in Thursday's trading session, following the release of the company's impressive 2024 annual results and pipeline updates. The biotechnology firm's stock price surge reflects investor optimism about its strong product performance and advancement in clinical trials across multiple therapeutic areas.

A key highlight from the annual report is the successful launch and sales performance of Stapokibart (CM310), an IL-4Rα antibody. The drug, approved for multiple indications including atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and seasonal allergic rhinitis, generated approximately RMB40 million in revenue within just three and a half months of its launch. This rapid market penetration demonstrates the drug's strong commercial potential and addresses significant unmet medical needs.

Keymed Biosciences also reported substantial progress across its diverse pipeline. Notably, the company's partnered Claudin 18.2 ADC (CMG901/AZD0901) with AstraZeneca is advancing in multiple clinical trials for various cancer indications. Additionally, other pipeline candidates such as CM313 (CD38 antibody), CM512 (TSLP x IL-13 bispecific antibody), and CM336 (BCMAxCD3 bispecific antibody) have shown promising results in their respective clinical studies. The company's focus on innovative therapies in oncology, immunology, and neurology has clearly resonated with investors, contributing to the stock's upward momentum.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1116736863"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116736863\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116736863?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-27 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116736863","market":"us","top_or_hot":-1,"title":"Stock Track | Keymed Biosciences Soars 5.17% Following Strong 2024 Annual Results and Pipeline Progress","media":"Stock Track","content":"<p>Shares of Keymed Biosciences (HKEX: 02162) are soaring 5.17% in Thursday's trading session, following the release of the company's impressive 2024 annual results and pipeline updates. The biotechnology firm's stock price surge reflects investor optimism about its strong product performance and advancement in clinical trials across multiple therapeutic areas.</p>\n\n<p>A key highlight from the annual report is the successful launch and sales performance of Stapokibart (CM310), an IL-4Rα antibody. The drug, approved for multiple indications including atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and seasonal allergic rhinitis, generated approximately RMB40 million in revenue within just three and a half months of its launch. This rapid market penetration demonstrates the drug's strong commercial potential and addresses significant unmet medical needs.</p>\n\n<p>Keymed Biosciences also reported substantial progress across its diverse pipeline. Notably, the company's partnered Claudin 18.2 ADC (CMG901/AZD0901) with AstraZeneca is advancing in multiple clinical trials for various cancer indications. Additionally, other pipeline candidates such as CM313 (CD38 antibody), CM512 (TSLP x IL-13 bispecific antibody), and CM336 (BCMAxCD3 bispecific antibody) have shown promising results in their respective clinical studies. The company's focus on innovative therapies in oncology, immunology, and neurology has clearly resonated with investors, contributing to the stock's upward momentum.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Keymed Biosciences Soars 5.17% Following Strong 2024 Annual Results and Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Keymed Biosciences Soars 5.17% Following Strong 2024 Annual Results and Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-27 10:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Keymed Biosciences (HKEX: 02162) are soaring 5.17% in Thursday's trading session, following the release of the company's impressive 2024 annual results and pipeline updates. The biotechnology firm's stock price surge reflects investor optimism about its strong product performance and advancement in clinical trials across multiple therapeutic areas.</p>\n\n<p>A key highlight from the annual report is the successful launch and sales performance of Stapokibart (CM310), an IL-4Rα antibody. The drug, approved for multiple indications including atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and seasonal allergic rhinitis, generated approximately RMB40 million in revenue within just three and a half months of its launch. This rapid market penetration demonstrates the drug's strong commercial potential and addresses significant unmet medical needs.</p>\n\n<p>Keymed Biosciences also reported substantial progress across its diverse pipeline. Notably, the company's partnered Claudin 18.2 ADC (CMG901/AZD0901) with AstraZeneca is advancing in multiple clinical trials for various cancer indications. Additionally, other pipeline candidates such as CM313 (CD38 antibody), CM512 (TSLP x IL-13 bispecific antibody), and CM336 (BCMAxCD3 bispecific antibody) have shown promising results in their respective clinical studies. The company's focus on innovative therapies in oncology, immunology, and neurology has clearly resonated with investors, contributing to the stock's upward momentum.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1116736863","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116736863","pubTimestamp":1743042275,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Keymed Biosciences  are soaring 5.17% in Thursday's trading session, following the release of the company's impressive 2024 annual results and pipeline updates. The biotechnology firm's stock price surge reflects investor optimism about its strong product performance and advancement in clinical trials across multiple therapeutic areas.A key highlight from the annual report is the successful launch and sales performance of Stapokibart , an IL-4Rα antibody. The drug, approved for multipl","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"凭借强劲的2024年年度业绩和管道进展，Keymed Biosciences股价飙升5.17%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"Shares of Keymed Biosciences (HKEX: 02162) are soaring 5.17% in Thursday's trading session, following the release of the company's impressive 2024 annual results and pipeline updates. The biotechnology firm's stock price surge reflects investor optimism about its strong product performance and advancement in clinical trials across multiple therapeutic areas.\nA key highlight from the annual report is the successful launch and sales performance of Stapokibart (CM310), an IL-4Rα antibody. The drug, approved for multiple indications including atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and seasonal allergic rhinitis, generated approximately RMB40 million in revenue within just three and a half months of its launch. This rapid market penetration demonstrates the drug's strong commercial potential and addresses significant unmet medical needs.\nKeymed Biosciences also reported substantial progress across its diverse pipeline. Notably, the company's partnered Claudin 18.2 ADC (CMG901/AZD0901) with AstraZeneca is advancing in multiple clinical trials for various cancer indications. Additionally, other pipeline candidates such as CM313 (CD38 antibody), CM512 (TSLP x IL-13 bispecific antibody), and CM336 (BCMAxCD3 bispecific antibody) have shown promising results in their respective clinical studies. The company's focus on innovative therapies in oncology, immunology, and neurology has clearly resonated with investors, contributing to the stock's upward momentum.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}